Association between prostate cancer and serum testosterone levels

Prostate

Volumn 53, Issue 3, 2002, Pages 179-182

  Zhang, Ping L ^a   Rosen, Seymour ^b   Veeramachaneni, Ravindra ^c   Kao, Jerry ^b   DeWolf, William C ^b   Bubley, Glenn ^b  

^a GEISINGER HEALTH SYSTEM   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Prostate cancer; Prostate needle biopsy; Prostatectomy; Testosterone

Indexed keywords

TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TESTOSTERONE BLOOD LEVEL;

ADULT; AGED; BIOPSY; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TESTOSTERONE;

EID: 0036843923     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10140     Document Type: Article

References (16)

1. Weinbauer GF, Barlett JM, Fingscheidt U, Tsonis CG, de Kretser DM, Nieschlag E. Evidence for a major role of inhibin in 3 the feedback control of FSH in the male rat. J Reprod Fertil 1989;85:355-362.
2. Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, Walsh PC. Influence of radical prostatectomy on serum hormone levels. J Urol 1988;160:449-453.
3. Lokeshwar BL, Hurkadli KS, Sheth AR, Block NL. Human prostatic inhibin suppresses tumor growth and inhibits clonogenic cell survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor. Cancer Res 1993;53:4855-4859.
4. Risbridger G, Thomas T, Gurusinghe CJ, McFarlane JR. Inhibinrelated proteins in rat prostate. J Endocrinol 1996;149:93-99.
5. Ying SY, Zhang Z, Huang G. Expression and localization of inhibin/activin subunits and activin receptors in the normal rat prostate. Life Sci 1997;60:397-401.
6. Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, IV: Anti-androgen treated patients. J Urol 1989; 141:1088-1090.
7. Guess HA, Heyse JF, Gormley GJ, Stoner E, Oesterling JE. Effect of finasteride on serum PSA concentration in men with benign prostatic hypertrophy. Urol Clin North Am 1993;20:627-636.
8. Oesterling JE, Roy J, Agha A, Shown T, Krarup T, Johansen T, Lagerkvist M, Gormley G, Bach M, Waldstreicher J. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: Effects of finasteride. Urology 1998; 51 (!Suppl 4A):58-63.
9. Ghosh PK, Ghosh D, Ghosh P, Chaudhuri A. Effects of prostatectomy on testicular androgenesis and serum levels of gonadotropins in mature albino rats. Prostate 1995;26:19-22.
10. Robinson MRG, Thomas BS. Effects of hormonal therapy on plasma testosterone levels in prostatic carcinoma. Br Med J 1971;4:391-394.
11. Drafta D, Proca E, Zamfir V, Schinder AE, Neacsu E, Store E. Plasma steroids in benign prostatic hypertrophy and carcinoma of the prostate. J Steroid Biochem 1982;17:689-693.
12. Habib FK, Lee IR, Stitch SR, Smith PH. Androgen levels in the plasma and prostatic tissues of patients with benign hypertrophy and carcinoma of the prostate. J Endocrinol 1976;71:99-107.
13. Hoffman MA, De Wolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000;163:824-827.
14. Zumoff B, Levin J, Strain GW, Rosenfeld RS, O'connor J, Freed SZ, Kream J, Whitmore WS, Fukushima DK, Hellman L. Abnormal levels of plasma hormones in men with prostate cancer: Evidence toward a "two-disease" theory. Prostate 1982; 3:579-588.
15. Ribeiro M, Ruff P, Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 1997;20:605-608.
16. Harper ME, Pierrepoint CG, Griffiths K. Carcinoma of the prostate: Relationship of pretreatment hormone levels to survival. Eur J Cancer Clin Oncol 1984;20:477-482.